Results 221 to 230 of about 207,050 (299)

Design and characterization of a novel prostate-specific membrane antigen-targeted radioligand modified with a fatty acid albumin binder for optimized circulation half-life. [PDF]

EJNMMI Radiopharm Chem
Zeng S, Gao X, Meng J, Yang X, Chi Z, Zhang Y, Zhou P, Li M, Zhang Y, Zhang X, Tang Y, Su Z, Tang J.   +12 more
europepmc   +1 more source

Focal therapy using a novel cooled laser device for prostate cancer: early trial results

BJU International, EarlyView.
Objectives To determine the short‐term oncological results and safety of the ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT‐PC) trial, the first phase II clinical trial of ProFocal® (Medlogical Innovations, Sydney, Australia), a novel, cooled laser focal therapy (cLFT) device for prostate cancer (PCa) treatment. Patients and Methods Men with
Jonathan Kam, Bishoy Hanna, Stuart Jackson, Stephen McCombie, George McClintock, Matthew J. Roberts, Jake Rahkala, Jeremy Teoh, Mohan Arianayagam, Bertram Canagasingham, Ahmed Saeed Goolam, Nicola Jeffery, Matthew Winter, Mohamed Khadra, Raymond Ko, Nicholas Mehan, Isaac Thangasamy, Celi Varol   +17 more
wiley   +1 more source

Advanced Image Analysis to Select Patients for Prostate Specific Membrane Antigen Radioligand Therapy and Assess Treatment Response. [PDF]

Adv Radiat Oncol
Floberg JM, Kyriakopoulos CE, Cho SY.
europepmc   +1 more source

Dosimetry and immunohistochemistry study to establish radiolabelled prostate-specific membrane antigen (PSMA) as a potential theranostic target in high-grade glioma treatment

Benger M, Krokos G, Daga K, Wright A, Bodi I, Marchi F, Jeljeli S, Livieratos L, Rosekilly J, Lavrador J, Kinsella S, Wood T, Marsden P, Gillett C, Blower P, Terry S, Mulholland N, Brazil L, Ashkan K, Cook G, Hammers A, Booth TC.   +21 more
europepmc   +1 more source

Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. [PDF]

Eur Urol
Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JJH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan AU, Pra AD, Ghadjar P, Sweeney CJ, Nickols NG, Karnes RJ, Shen J, Rettig MB, Czernin J, Ross AE, Lee Kiang Chua M, Schaeffer EM, Calais J, Boutros PC, Reiter RE.   +26 more
europepmc   +1 more source

Long‐term outcomes of cribriform‐positive and cribriform‐negative prostate cancer treated with radical prostatectomy in the ProtecT trial

BJU International, EarlyView.
Objectives To retrospectively analyse the results of the Prostate Testing for Cancer and Treatment (ProtecT; ClinicalTrials.gov identifier: NCT02044172) trial to establish the association between cribriform‐positive and ‐negative prostate cancer (PCa) and the 15‐year risk of metastasis or death from PCa in patients who underwent radical prostatectomy ...
Nikita Sushentsev, Anne Y. Warren, Richard Colling, Clare Verrill, Ekaterina Pazukhina, Oleg Blyuss, Alexey Zaikin, Tyler M. Seibert, Tristan Barrett, Jon Oxley, Ian G. Mills, Richard J. Bryant, J. Athene Lane, Jenny L. Donovan, David E. Neal, Freddie C. Hamdy   +15 more
wiley   +1 more source

Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen. [PDF]

PLoS One
Das G, Ptacek J, Campbell J, Li X, Havlinova B, Noonepalle SK, Villagra A, Barinka C, Novakova Z.   +8 more
europepmc   +1 more source

Guideline of guidelines: pelvic lymph node dissection at time of radical prostatectomy

BJU International, EarlyView.
Objective To provide a comprehensive review, analysis and critique of guidelines from various oncological and urological organisations regarding the use pelvic lymph node dissection (PLND) in men undergoing radical prostatectomy (RP) for primary treatment of prostate cancer (PCa).
Jonathon Carll, Jonathan Walbaum, Carlos Delgado, Elena Berg, Declan G. Murphy, Marlon Perera, Ahmed Adam, John Yaxley, Nathan Lawrentschuk   +8 more
wiley   +1 more source

Therapeutic Challenges in Metastatic Castration-Resistant Prostate Cancer: A Case Study and Review of Prostate-Specific Membrane Antigen-Targeted Therapy Failures in Highly Prostate-Specific Membrane Antigen-Avid Disease. [PDF]

Cureus
Moghrabi S, Al-Houwari R, Ruzzeh S, Al-Ibraheem A.   +3 more
europepmc   +1 more source

Oligoprogressive renal cell carcinoma: What is the role of surgery?

BJU International, EarlyView.
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Chiara Re, William H.J. Ince, Leo Bickley, James P. Blackmur, Mouhamad H. Ismail, Justicia Kyeremeh, Teele Kuusk, Eva Mendes Serrao, James O. Jones, Grant D. Stewart   +9 more
wiley   +1 more source